Today: 14 December 2025
Subscribe
Browse Category

Pharmaceuticals News 14 November 2025 - 18 November 2025

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 18, 2025): $199 Wegovy/Ozempic Intro Offer Drives Focus; Controlling Shareholder Sells ConvaTec Stake; NVO Edges Lower

Published November 18, 2025 Summary: Novo Nordisk (NYSE: NVO) remains in the spotlight after rolling out a U.S. self‑pay price cut for Wegovy and Ozempic—plus a two‑month $199 introductory offer for new patients—while its controlling shareholder Novo Holdings exited its
18 November 2025
 ·  ·  ·  ·  · 
Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Why OLMA Stock Is Exploding Today Olema Pharmaceuticals didn’t publish a press release or file anything with the SEC this morning. Yet, its stock rocketed nearly threefold in pre‑market trading on Tuesday, November 18, 2025. TipRanks+1 The real catalyst comes
18 November 2025
 ·  ·  ·  ·  · 
Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals (TNXP) Jumps as TONMYA, First New Fibromyalgia Drug in 15 Years, Hits U.S. Pharmacies – November 17, 2025

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) moved sharply higher today after the company confirmed that TONMYA™ (cyclobenzaprine HCl sublingual tablets), its newly approved fibromyalgia treatment, is now commercially available by prescription across the United States. GlobeNewswire+1 TONMYA Officially Launches in
17 November 2025
 ·  ·  ·  ·  · 
Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

Galmed Pharmaceuticals (GLMD) Soars on New Cancer Drug Combo Data: What Today’s Breakthrough Means for Investors – November 17, 2025

As of this afternoon, Galmed Pharmaceuticals shares were changing hands around $1.18, up roughly 13% on the day, with more than 41 million shares traded—massively above the stock’s usual daily volume. TipRanks What Galmed Announced Today From its headquarters in
17 November 2025
 ·  ·  ·  ·  · 
Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals (JAZZ) Soars on Breakthrough Ziihera Phase 3 Results in Gastroesophageal Cancer – Key Updates for 17 November 2025

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is in the spotlight today after announcing positive Phase 3 data for its cancer drug Ziihera® (zanidatamab‑hrii) in a large global trial for HER2‑positive gastroesophageal adenocarcinoma (GEA). The news has triggered sharp pre‑market moves in
17 November 2025
 ·  ·  ·  · 
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far. Reuters+1 The move deepens J&J’s bet on
17 November 2025
 ·  ·  ·  ·  ·  ·  ·  · 
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Stock on November 15, 2025: Pricing Deal, Oral‑Obesity Pill Timeline, Q3 Beat Put Shares Near $1T — Outlook & Risks

Updated: November 15, 2025 Key takeaways Where LLY stands today (Nov. 15, 2025) As of 00:40 UTC on Nov. 15, LLY is ~$1,025 (day range $1,003–$1,033). The 52‑week range is roughly $624–$1,034, and third‑party dashboards peg market cap in the
15 November 2025
 ·  ·  ·  ·  · 
Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Pfizer Completes $10 Billion Metsera (MTSR) Buyout as Nasdaq Delists Stock Today

Metsera Inc. (NASDAQ: MTSR) stops trading today, November 14, 2025, as Pfizer closes its up to $10 billion obesity-drug acquisition. Here’s what Metsera shareholders and obesity-market investors need to know about the deal terms, CVR, delisting, and future milestones. Date:
14 November 2025
 ·  ·  ·  ·  ·  · 
Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb (BMY) Shares Slide as Milvexian Heart Trial Halted After Interim Review – What Investors Need to Know Today (14 November 2025)

Bristol Myers Squibb and Johnson & Johnson end a key Phase 3 heart study for milvexian, sending BMY stock lower even as the pharma giant leans on a strong growth portfolio and fresh financing firepower. Bristol-Myers Squibb Company (NYSE: BMY)
14 November 2025
 ·  ·  ·  ·  ·  · 
Anavex Life Sciences (AVXL) Stock Plunges After EMA Issues Negative Trend Vote on Alzheimer’s Drug

Anavex Life Sciences (AVXL) Stock Plunges After EMA Issues Negative Trend Vote on Alzheimer’s Drug

Anavex Life Sciences (NASDAQ: AVXL) tumbled on November 14, 2025 after Europe’s drug regulator delivered a negative trend vote on its Alzheimer’s candidate blarcamesine. The company plans a CHMP re-examination and a fresh meeting with the FDA. Here’s what happened
14 November 2025
 ·  ·  ·  ·  · 
1 … 8 9 10 11 12 … 18
Go toTop